• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Casa Sollievo della Sofferenza,Istituti di Ricovero e Cura a Carattere Scientifico

    EST. 1956
    3,205论文总数
    12.6万引用总数

    论文量&引用量时间轴

    机构学者

    论文(3205)

    年份
    起
    –
    止
    排序
    1Liver Metastases in Advanced Urothelial Carcinoma (ARON-2): Do Pembrolizumab and Avelumab Make a Difference in a Poor-Prognosis Scenario?
    Linda Cerbone,Giandomenico Roviello,Fabio Calabrò, Tarek Taha,Enrique Grande, Kirstin Binz,Ravindran Kanesvaran, Alina Pirstuk,Ondřej Fiala, Javier Molina-Cerrillo,Teresa Alonso-Gordoa,Alessandro Rizzo,

    Background:Over the past decade, the treatment landscape for metastatic urothelial carcinoma (mUC) has improved significantly with the introduction of immunotherapy, targeted agents, and antibody-drug conjugates. The median overall survival (mOS) reached 36.7 months in cisplatin-eligible and 25.6 months in cisplatin-ineligible patients in the first-line setting and over 10 months post-platinum failure. However, liver metastases remain a known poor prognostic factor. Methods:We conducted a retrospective analysis of mUC patients treated at 79 global institutions. Two cohorts were defined: cohort 1 included patients who progressed after platinum-based therapy and received pembrolizumab, and cohort 2 included patients who received avelumab as maintenance therapy. Treatments were administered between 1 January 2016 and 31 October 2024. Results:Cohort 1 (n = 1,341) had an mOS of 17.5 months. Patients without liver metastases had significantly longer OS than those with liver involvement (20.1 vs. 9.4 months, p <0.001). Among patients with liver metastases, OS was 11.8 months in males vs. 5.8 months in females (p = 0.066). OS was longer in those with BMI ≥25 kg/m² (14.1 vs. 8.1 months, p = 0.028) and better ECOG-PS (ECOG 0: 17.0 months; ECOG 1: 9.8; ECOG ≥2: 3.1; p <0.001). Cohort 2 (n = 291) had an mOS of 25.8 months. Again, OS was longer in patients without liver metastases (27.0 vs. 16.4 months, p <0.001). Among those with liver involvement, OS was 14.7 months in males and 20.0 months in females (p = 0.310). Patients with BMI ≥25 had non-reached OS versus 17.1 months in those with lower BMI (p <0.001). ECOG-PS remained a strong prognostic factor (NR for ECOG 0; 14.7 months for ECOG 1; 4.6 months for ECOG ≥2, p <0.001). Conclusion:Liver metastases are associated with significantly reduced survival in patients with mUC receiving immunotherapy. However, both pembrolizumab and avelumab demonstrated improved outcomes compared with historical chemotherapy data. These findings underscore the need for personalized treatment strategies in high-risk subgroups.

    2026Frontiers in immunology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Placenta Accreta Spectrum: Data Review of PAS Cases in an Italian Tertiary Level Unit Successfully Managed by Multidisciplinary Team Care
    Tiziana Palladino, Sara Paola Mariotti
    2026International Journal of Obstetric Anesthesia(2026)
    引用
    AI阅读
    加入学术空间
    3Abstract PS4-08-21: Neoadjuvant Breast Cancer in a Real Life Experience in Southern of Italy
    M. Ciccarese, L. Orlando, F. Giotta, M. Di Millo, M. Morritti, L. Ciuffreda, S. Bambace, F. Giuliani, O. Custodero, S. Bruno, S. Stucci, M. Moschetta,

    Neoadjuvant therapy (NAT) is a cornerstone of breast cancer management (1). However, real-world criteria for patient selection remain poorly defined outside the context of clinical trials. A previous Italian study, which included southern regions, highlighted substantial variability in NAT utilization (2,3). According to EUSOMA, the use of NAT represents a key quality indicator within breast unit care pathways (4). This study aimed to investigate which centers in the Apulia region offer NAT, the criteria employed for patient selection, perceived barriers to its use, and the level of adherence to EUSOMA guidelines. Twelve regional Breast Units (BUs) and five of the seven spoke centers in Apulia participated in the survey (one BU did not respond). The survey was conducted between October and November 13, 2024, and analyzed data from the preceding six months. It consisted of three thematic sections: • C1: Organizational structure, multidisciplinary team (MDT) case volume, proportion of NAT-eligible cases, and the interval between the end of NAT and surgery. • C2: Proportion of NAT-eligible cases by tumor subtype (HER2+, ER/PgR+/HER2-, triple-negative). • C3: Subtype-specific barriers to NAT, with relative relevance ratings. The results are described in table 1 Barriers to Neoadjuvant Therapy (NAT) Identified by Clinicians: Breast Units reports • HER2+ cases: 41% considered tumor size ≤2 cm and node-negative status (T≤2/N0) as a barrier to NAT. • ER/PgR+ cases: 100% identified T1-T2 and node-negative status (T1-T2/N0) as a limiting factor. • Triple-negative breast cancer (TNBC): 83% considered tumor size ≤1 cm as a barrier. Spokes reports: • 80% cited T≤1 cm and node-negative status (T≤1 cm/N0) as a barrier in HER2+ cases. • 100% cited T1-T2 with N0-N1 status (T1-T2/N0-1) as a limitation in ER/PgR+/HER2- cases. • 100% identified T≤1 cm/N0 as a barrier in TNBC cases. Although limited to a six-month period, the findings reflect the heterogeneity previously reported in broader studies. NAT rates and surgery timing were consistent with guideline recommendations, despite an unselected patient population. Tumor and nodal size—particularly in small, high-risk subtypes—emerged as key limiting factors. Spoke centers expressed greater concern about the risk of over-treatment in low-volume, high-risk scenarios. Further analyses will investigate treatment decision-making and access to clinical trials. M. Ciccarese, L. Orlando, F. Giotta, M. Di Millo, M. Morritti, L. Ciuffreda, S. Bambace, F. Giuliani, O. Custodero, S. Bruno, S. Stucci, M. Moschetta, S. Pisconti, G. Palmiotti, E. De Matteis, G. Cairo, S. Cinieri. Neoadjuvant breast cancer in a real life experience in Southern of Italy [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-08-21.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    4Isolated Medial Meniscus Allograft Transplant Intraoperatively Restores Anteroposterior Knee Stability As Effectively As Isolated Anterior Cruciate Ligament Reconstruction.
    Stefano Di Paolo, Piero Agostinone, Luca Ambrosini, Margherita Bonaiuti,Gian Andrea Lucidi,Luca Macchiarola,Alberto Grassi,Stefano Zaffagnini

    PURPOSE:To compare the capacity of isolated medial or lateral meniscus allograft transplantation (MAT) and isolated anterior cruciate ligament (ACL) reconstruction (ACLR) to reduce pre-operative knee laxity in vivo. Isolated MAT was hypothesized to restore knee stability comparably to isolated ACLR. METHODS:All surgical procedures performed with intraoperative navigation were retrospectively analyzed. Patients with post-meniscectomy syndrome and intact ACL undergoing medial or lateral MAT (MAT-M and MAT-L groups) were matched 1:1 by age and sex to patients with intact menisci undergoing ACLR (ACLR-M and ACLR-L groups, respectively). Intraoperative anteroposterior (AP), internal/external rotation, varus/valgus and pivot-shift (PS) laxity were quantified using the navigation system before and after surgery. Repeated-measures ANOVA was used to compare laxity between groups across pre- and post-operative states. Statistical significance was set at p < 0.05. RESULTS:From a total of 232 patients, 36 were selected: 8 in the MAT-M group, 8 in the ACLR-M group, 10 in the MAT-L group and 10 in the ACLR-L group. MAT-M reduced pre-operative AP laxity with no statistically significant difference compared to ACLR, across all measured parameters, including AP translation at 30° and 90° of flexion, internal/external rotation and varus-valgus. Conversely, ACLR was a significantly more effective stabilizer compared to MAT-L, demonstrating a greater reduction in AP laxity at 30° (43.2% vs. 37.2%, p = 0.045) and 90° of flexion (62.6% vs. 36.3%, p = 0.007), and PS area (62.5% vs. 32.5%, p = 0.002). CONCLUSIONS:In patients with chronic post-meniscectomy syndrome, isolated MAT-M restored AP knee stability comparably to isolated ACLR, suggesting that the medial meniscus acts as a primary stabilizer in this population. In contrast, isolated MAT-L was significantly less effective than ACLR in controlling AP and PS laxity, despite significantly reducing it. These findings highlight the critical, compartment-specific biomechanical role of the menisci. LEVEL OF EVIDENCE:Level III.

    2026Knee surgery, sports traumatology, arthroscopy official journal of the ESSKA(2026)
    引用
    AI阅读
    加入学术空间
    5Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial
    Bruno Meduri, A. Baldissera,Cinzia Iotti,Luc J.E.E. Scheijmans,Marcel R. Stam,Salvatore Parisi,Liesbeth Jorinne Boersma,Ilario Ammendolia,Eveline Koiter, Paola Canino,Dianne M. Busz,Marika C. Stenfert Kroese,

    Purpose The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). Patients and Methods We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958 ) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). Results Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. Conclusion At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.

    2026Journal of Clinical Oncology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3205 篇论文

    合作机构(99)

    巴里阿尔多·莫罗大学合作论文 384
    福贾大学合作论文 296
    罗马大学合作论文 230
    意大利科学领域恢复与治疗研究所合作论文 180
    圣心天主教大学合作论文 177
    那不勒斯费德里克二世大学合作论文 156
    都灵大学合作论文 133
    米兰大学合作论文 132
    帕多瓦大学合作论文 129
    卡塔尼亚大学合作论文 118

    机构统计